FGP
ACAD icon

Freestone Grove Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Freestone Grove Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Buy
+46,443
New +$1.11M 0.01% 467

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Freestone Grove Partners's ACAD Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 46,443 shares worth $1.03M. The stake represents 0.01% of the portfolio and ranks #467 among its holdings.

340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Freestone Grove Partners held 46,443 shares of Acadia Pharmaceuticals worth $1.03M as of Q1 2026.
  • Acadia Pharmaceuticals was a new Freestone Grove Partners position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #467 holding.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.